GROUP AT A GLANCE WHAT WE DO & WHERE WE DEVELOP, MANUFACTURE AND MARKET A BROAD RANGE OF BRANDED AND NON-BRANDED GENERIC PHARMACEUTICAL PRODUCTS ACROSS THE MIDDLE EAST AND NORTH AFRICA, THE UNITED STATES AND EUROPE.
WE ARE ALSO A LEADING LICENSING PARTNER IN THE MENA REGION.
OUR OPERATIONS SPAN OVER 45 COUNTRIES AND ARE CONDUCTED THROUGH THREE BUSINESS SEGMENTS CORE BUSINESS DIVISION: GEOGRAPHICAL AREA: US GENERICS TOP PRODUCTS: SELLING ORAL GENERIC Amoxicillin PRODUCTS ACROSS THE US Doxycycline Isosorbide mononitrate Methocarbamol Prednisone Long-standing presence in the 2012 REVENUE: US oral generics market Focus on quality manufacturing $103.7m and high service levels 33.0 % Strong emphasis on niche products, including controlled substances Leveraging our efficient and lower cost US FDA approved manufacturing facilities in Jordan and Saudi Arabia More information see page 30 41 products in 103 dosage 1 View our business model on page 7 forms and strengths 8 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012 CORE BUSINESS DIVISION: GEOGRAPHICAL AREA: US, Europe, MENA INJECTABLES TOP PRODUCTS: SELLING SPECIALISED Fentanyl Hydromorphone INJECTABLE PRODUCTS Iron gluconate Morphine GLOBALLY Ondansetron A leading global manufacturer of quality sterile injectables 2012 REVENUE: US FDA approved manufacturing facilities in the US, Portugal $470.0m and Germany 48.9 % Range of manufacturing capabilities including sterile liquid, powder, lyophilised and cytotoxic products Broad product portfolio including CNS, anti-infective, cardiovascular and oncology products More information see page 26 179 products in 361 dosage forms and strengths View our business model on page 7 CORE BUSINESS DIVISION: GEOGRAPHICAL AREA: MENA BRANDED TOP PRODUCTS: SELLING BRANDED GENERICS Amoclan Blopress Omnicef AND IN-LICENSED PATENTED Suprax Zomax PRODUCTS ACROSS THE MENA REGION Fifth largest pharmaceutical manufacturer in the MENA region 36.9% of Branded sales from in-licensed products 2012 REVENUE: 1,684 reps targeting physicians $528.9m and pharmacists across the region 19.7 % Strong anti-infective franchise and increasing focus on cardiovascular, diabetes and CNS products US FDA approved manufacturing facilities in Jordan and Saudi Arabia More information see page 21 606 products in 1,630 dosage forms and strengths View our business model on page 7 KEY: 26 MANUFACTURING PLANTS 6 R&D CENTRES 1 Products marketed during 2012 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012 9
